As
Pfizer Inc.
forecasts strong sales this year for its Covid-19 vaccine and treatment, the drugmaker is on the hunt for deals to bolster its pipeline of experimental products.
Pfizer said Tuesday that surging sales of its Covid-19 treatment and continued demand for its shots should boost the company’s revenue to around $100 billion this year. The company estimated that sales of its antiviral pill Paxlovid will reach about $22 billion while the vaccine will add $32 billion.
That is on top of last year’s sales of $36.8 billion for the vaccine, also known as Comirnaty, the highest annual sales total for any pharmaceutical product. Paxlovid sales last year totaled $76 million.
The company has done a handful of recent acquisitions and partnerships to bolster its pipeline of drugs and vaccines, including…
